AstraZeneca PLC (AZN,AZN.L), a Swedish-British pharmaceutical and biotechnology company, on Thursday priced a three-tranche bond offering totalling $2 billion through its wholly owned subsidiary AstraZeneca Finance LLC.
The closing is expected on March 2.
The offering comprises $650 million of 4.000% notes due March 2, 2031, $600 million of 4.300% notes due March 2, 2033, and $750 million of 4.600% notes due March 2, 2036.
The company said that the net proceeds will be used for general corporate purposes, including potential refinancing of existing indebtedness.
On Wednesday, AstraZeneca closed trading, 0.70% lesser at GBp 15,218 on the London Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.